Epidemiologic studies of SLE performed as early as the 1960s have noted that SLE is not only more common, but also more severe among ethnic minority populations. Subsequent studies have generated vigorous debate over the extent to which genetic, environmental or other factors account for these differences. However, most epidemiologic studies of ethnicity and SLE treat ethnic groups as homogeneous categories, thus obliterating the genetic, cultural, and socioeconomic diversity that exists within groups that could contribute to the observed differences. Using genetic ancestry rather than self-identified ethnicity provides some advantages when investigating ethnicity, genetics, and disease characteristics. This approach does not assume that racial or ethnic groups are homogeneous but rather capitalizes on genetic heterogeneity within groups to more effectively dissect the relationship between ethnicity, genetics, and disease risk. The proposed project is designed to extend our genetic epidemiologic investigations of ancestry and SLE disease characteristics and will take advantage of a novel tool, the "ImmunoChip". This unique genotyping array is comprised of ~200,000 genetic markers which were selected to provide detailed coverage of recently identified autoimmunity gene loci, and are also informative for comprehensive genetic ancestry. The proposed project will benefit from an extensive collaborative network, which has supported characterization of the UCSF Lupus Outcome Study (LOS) participants, and other SLE cohorts, for the ImmunoChip genetic marker set. The availability of SES and other covariate information on LOS participants will allow us to control for these potentially important factors in our analyses. More specifically, we are proposing the following aims: 1) characterize the relationship between genetic ancestry, including both continental and intra-continental ancestry, and SLE disease characteristics, including age at SLE diagnosis, renal disease, anti-dsDNA autoantibody production, and cumulative damage;and 2) determine whether recently identified genetic loci emerging from genome wide association and other genetic studies are risk factors for specific SLE manifestations. For gene variants associated with specific SLE manifestations, we will characterize the extent to which these variants explain ancestry associations demonstrated in Aim 1. This project will advance the field by elucidating more proximate factors that influence ethnic disparities in SLE, and our focus on health disparities synergizes well with the overall theme of our MCRC.

Public Health Relevance

Substantial prior research documents ethnic differences in SLE outcomes, with patients of non-European ancestry experiencing more severe disease and poorer outcomes overall. Recent research suggests that genetic ancestry contributes importantly to these health disparities, over and above differences that may be attributed to socioeconomic or other non-genetic factors. Elucidation of the more proximate causes of health disparities in SLE will be critically important for efforts to decrease disparities and improve outcomes for all patients. The current project will utilize unique clinical and genetic resources for these studies.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Comprehensive Center (P60)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Yelin, Edward; Yazdany, Jinoos; Tonner, Chris et al. (2015) Interactions between patients, providers, and health systems and technical quality of care. Arthritis Care Res (Hoboken) 67:417-24
Armstrong, D L; Zidovetzki, R; Alarcón-Riquelme, M E et al. (2014) GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region. Genes Immun 15:347-54
Yazdany, Jinoos; Marafino, Ben J; Dean, Mitzi L et al. (2014) Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation. Arthritis Rheumatol 66:2828-36
Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Joseph, Lawrence et al. (2014) Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 73:138-42
Drenkard, C; Yazdany, J; Trupin, L et al. (2014) Validity of a self-administered version of the brief index of lupus damage in a predominantly African American systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 66:888-96
Yazdany, Jinoos; Tonner, Chris; Schmajuk, Gabriela et al. (2014) Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:1447-55
Lawson, Erica F; Hersh, Aimee O; Trupin, Laura et al. (2014) Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup. Arthritis Care Res (Hoboken) 66:717-24
Guthridge, Joel M; Lu, Rufei; Sun, Harry et al. (2014) Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet 94:586-98
Kaiser, Rachel; Tang, Ling Fung; Taylor, Kimberly E et al. (2014) A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. Arthritis Rheumatol 66:1882-7
Solomon, Daniel H; Tonner, Chris; Lu, Bing et al. (2014) Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:1152-8

Showing the most recent 10 out of 103 publications